A recent analysis of adverse drug reactions by Indian Pharmacopoeia Commission revealed that combinations of beta-blockers ...

New international consensus guidelines were developed through a research method, known as a Delphi process, that used a ...

Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...

The most effective antipsychotic drug for people with treatment-resistant schizophrenia is clozapine. Yet, across the world, ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

To date, almost 400 reports of acute pancreatitis have been received from people using GLP-1 drugs such as Mounjaro, Wegovy, ...

Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world ...

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Researchers at Brown University’s School of Public Health found that children exposed to higher levels of triclosan may be ...

National DRESS Syndrome Day 2025 Highlights "Faces of DRESS" to Advocate for Urgent Scientific Investment RICHMOND, Va., July 2, 2025 /PRNewswire/ -- In ...

Discover a recent report that states that, although GLP-1 medicines are generally well tolerated, there have been cases of ...